Americas Insomnia Market is Expected to Grow at a rate of 4.52% CAGR during Forecast Period of 2022 -2030

Pune, India, 2022 /MRFR Press Release/- Market research future published a half cooked research report on Americas Insomnia Market. 

Market Highlights

The Americas Insomnia Market is expected to reach USD 5240 Million by 2030 at 4.52% CAGR during the forecast period 2022-2030.

In America the insomnia is common sleeping disorder found majorly in the North American Region. This region has large industrialization and the number of working people are more. The work force is comprised of both men and women. The insomnia problem is majorly seen in the women in North American Region. The market is majorly driven by the constantly changing shift hours for the people. Also for women the disturbance in sleep is created by the snoring of her partner, small children and consciousness of getting up early in morning for her work. There are many more such reasons that lead to sleeping disorders in both men and women.

Americas Insomnia Market Players
There are number of players working for the treatment and care of insomnia, these are local and global level players. Those are Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan),  Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US),  Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US).

Meda Consumer Healthcare Inc. is a US based company who have variety of pills used to treat sleeping disorders. The company has three medicine known as MidNite Sleep aid, MidNite PM for Pain and MidNite for Menopause. The company has significantly expanded its leadership in sleep and alertness aid segment and Vivarin alertness aid. The company has also acquired the MidNite brand.

Vanda Pharmaceuticals Inc. is a US based biopharmaceutical company which focuses on the development of commercialization of innovative therapy and is constantly working for the unmet need and for the improvement of the patients’ lives.  The product for insomnia Helitoz trasimelteon which is in capsule form got US FDA approval in January 2014. The medicine is used to treat 24- hours sleep wake disorder. Also the other product Hetlioz got approval from European Commission in July 2015 to launch the product in European market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Americas Insomnia Market Research Report

Johnson & Johnson, the Boston, California and London facilitated the innovation centers and include exciting technologies like 3-D printing announced the early-stage collaborations for recent research and development alliances for insomnia and other unmet medical diseases. In U.S., near about 2.4 million Americans have schizophrenia, affected men and women equally. The company has drug INVEGA SUSTENNA for the treatment of insomnia along with other symptoms of disease. The drug is in phase three of clinical trials.

Eisai, Co. is an old company which into making medicine for the insomnia. Company is a larger player in the Japanese market. Company has acquired the manufacturing rights to make API and as well the IPR right from Chugai and Roche to treat insomnia. The marketing authorization are transferred as well as the transition of marketing activities for Rohypnol from Chugai to Eisai and are applicable from April 1, 2017.

Figure 1           America Insomnia Market Players, Market Share, 2016 (%)

Segmentation:
The Americas insomnia market is segmented on the basis of, types of therapy, drug formulation and by type of disease. On the basis of types of therapy market is segmented into pharmacological therapy and non-pharmacological therapy. On the basis of the pharmacological therapy is sub-segmented into Benzodiazepines, Non-benzodiazepines, Melatonin receptor agonists and others. Likewise on the basis of the non-pharmacological therapy is also sub-segmented into Relaxation therapy, Cognitive behavioral therapy, Sleep hygiene education, Stimulus Controls, Paradoxical intension and others.  On the basis of drug formulation the drugs are being formulated in capsules, tablets and others. Whereas on the basis of type of disease it includes poor quality of sleep, sleep maintenance and others.